Fill out the fields and click "Show data". The Total Return Calculator will provide you with the current value of your Fresenius shares and the return. Moreover, the Calculator shows the share price performance during the selected period.
Contact
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com
Related Links
Interactive Tool
Fresenius Helios is the leading private healthcare provider in Europe serving with around 140 clinics and numerous outpatient facilities about 27 million people annually. Together with Fresenius Kabi, a provider of healthcare products for the critically and chronically ill, Fresenius Helios is part of the Fresenius healthcare group. With its 130,000 employees of the Helios Group in Germany and Quirónsalud in Spain and Latin America, Fresenius Helios generated total sales of more than 13.5 billion euros in 2025.
Helios Germany operates more than 80 hospitals, about 200 outpatient care centers with, six prevention centers and 30 occupational medicine centers. Helios treats approximately 5.6 million patients annually, of whom 4 million are outpatients. Since its beginnings, Helios has focused on measurable, high medical quality as well as data transparency and is better than the German average in more than 90 percent of the quality targets. With about 80,000 employees, Helios generated sales of €8.1 billion in 2025. With its own 35 training centers, Helios represents education and training in the healthcare sector. Helios Germany is headquartered in Berlin.
Quirónsalud has 57 hospitals, including seven in Latin America, around 130 outpatient centers and more than 300 occupational risk prevention centers, and treats approximately 22 million patients annually, of whom 20 million are outpatients. Quirónsalud has about 50,000 employees and generated sales of more than €5.4 billion in 2025.
Contact
Helios Kliniken GmbH
Friedrichstr. 136
10117 Berlin
Germany
T +49 30 521 321-0
Fresenius is one of the top 40 companies in Germany in terms of market capitalization and is included in Germany's leading index, the DAX. We are also listed in the STOXX Europe 600 Health Care, the FTSEurofirst 300 and the DAXsector Pharma & Healthcare indices.
Fresenius ordinary shares are traded on the stock exchanges in Frankfurt, Düsseldorf and Munich.
At the end of July 2022, Fresenius SE & Co. KGaA's capital stock was 563,237,277 ordinary shares. The shares are notional no-par-value shares. Each share represents €1.00 of the capital stock.
Basic Share information
| Ordinary share | |
|---|---|
Securities identification no. | 578 560 |
Ticker symbol | FRE |
ISIN | DE0005785604 |
Bloomberg symbol | FRE GR |
Reuters symbol | FREG.de |
Main trading location | Frankfurt/Xetra |
Paying agent | Deutsche Bank AG, Taunusanlage 12, 60325 Frankfurt am Main, Germany |
Key data
| 2024 | 2023 | 2022 | |
|---|---|---|---|
Numbers of shares | 563,237,277 | 563,237,277 | 563,237,277 |
Stock exchange quotation1 in € | |||
High | 34.85 | 31.11 | 37.88 |
Low | 24.54 | 23.46 | 20.04 |
Year-end quotation | 33.54 | 28.07 | 26.25 |
Market capitalization2 in million € | 18,891 | 15,810 | 14,785 |
Total dividend distribution in million € | 5633 | - | 518 |
Dividend per share in € | 1.003 | - | 0.92 |
Earnings per share in €4 | 3.11 | 2.67 | 3.08 |
-
- 1 Xetra closing price on the Frankfurt Stock Exchange
- 2 Total number of ordinary shares multiplied by the respective Xetra year-end quotation on the Frankfurt Stock Exchange
- 3 Proposal
- 4 Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items
Contact
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com
Related Links
Interactive ToolEvent
February 25, 2026 - 01:30 pm | Bad Homburg, Germany
Fresenius Kabi specializes in essential and lifesaving medicines alongside technologies for infusion, transfusion, and medical nutrition. The product portfolio comprises a range of highly complex biopharmaceuticals, medical nutrition, medical technologies, and IV generic drugs and solutions.
The products and services are used for the therapy and care of critically and chronically ill patients. Fresenius Kabi is a world market leader in intravenous drugs and parenteral nutrition.
With more than 41,000 employees and present in over 100 countries, Fresenius Kabi reported more than €8.5 billion revenue in 2025.
Contact
Fresenius Kabi AG
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 686-0
You will be now forwarded to the Fresenius Career page.
If the automatic redirect is not working, please click on the following link.
Fresenius Kabi has agreed to collaborate with Phlow Corporation, a public benefit company, to expand access to affordable sterile injectables formulated for U.S. children’s hospitals and to help strengthen the supply chain for U.S.-sourced API and essential medicines. The companies will work together to supply private-labelled products, co-develop and manufacture novel products and make essential medicines rapidly available in the event of a public health emergency.
Fresenius Kabi has agreed to collaborate with Phlow Corporation, a public benefit company, to expand access to affordable sterile injectables formulated for U.S. children’s hospitals and to help strengthen the supply chain for U.S.-sourced API and essential medicines. The companies will work together to supply private-labelled products, co-develop and manufacture novel products and make essential medicines rapidly available in the event of a public health emergency.
Ensure financial flexibility, maintain our investment grade rating, limit refinancing risks and optimize the cost of capital are the main objectives in Fresenius’s financing strategy.
To remain financially flexible, we maintain adequate liquidity headroom. We are committed to our investment grade rating, which provides us with advantages with respect to market access and funding costs.
Our refinancing risks are limited due to a balanced maturity profile that is characterized by a broad range of maturities with a high proportion of mid- and long-term debt up to 2034. Relevant financing instruments include bonds, Schuldschein Loans and bank loans. In addition, Fresenius maintains a commercial paper program.
Another key objective of Fresenius’ financing strategy is to optimize the cost of capital by employing an adequate mix of equity and debt.
In 2025, deleveraging will remain a key priority. Fresenius has upgraded its leverage target corridor to 2.5 to 3.0x net debt/EBITDA (previously 3.5 to 3.0x). This allows us to stay financially flexible while solidifying our solid investment grade rating.
Fresenius Group
1 Prior-year figures have been adjusted due to the deconsolidation of Fresenius Medical Care operations
2 Before special items
3 At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures, including lease liabilities, including Fresenius Medical Care dividend; Net debt adjusted for the valuation effect of the exchangeable bond
Contact
Director Investor Relations
T: +49 (0) 6172 608-2486
elisabeth.truckenbrodt@fresenius.com
Related Links
Interactive Tool
Group Communications
Here you can find a variety of information:
“A pharmacy today? We need to expand it or add something new to it.” (Dr. Eduard Fresenius, Founder, 1912)
News
-
Brief News
DRG inflator 2027 expected at 4.85%
On September 15, 2026, the base wage rate, or rate of change, was announced. It reflects the development of health insurance revenues, based on contributions, and is the key parameter for determining the annual increase in hospital reimbursement in Germany for 2027, the so-called DRG inflator.Download the full Market Briefing for details on the calculation, implications for the sector, and upcoming milestones in hospital funding.
September 16, 2026 · Fresenius
-
Fresenius establishes venture fund of more than €200 million to drive healthcare innovation
![]()
Fresenius establishes venture fund of more than €200 million to drive healthcare innovation
Fresenius is further expanding its access to innovation networks through its own corporate venture capital fund.
July 23, 2026 · Fresenius
-
Fresenius Opens Innovation Center for Medical Nutrition in Bad Homburg
![]()
Fresenius Opens Innovation Center for Medical Nutrition in Bad Homburg
Fresenius today officially opened its new Innovation Center in Bad Homburg, Germany, marking a major milestone in strengthening research, development, and innovation in medical nutrition.
June 02, 2026 · Fresenius Kabi
-
Brief News
AI assistant enhances access to Investor Relations information
Today, Fresenius has launched the AI-powered assistant – “AskFRE” – on its Investor Relations (IR) website, marking an important step in advancing its digital capital markets communications. The solution is a joint initiative of the Fresenius AI Center of Excellence and the Investor Relations team.With AskFRE, visitors can now interact with an integrated AI chatbot that provides direct answers to capital market-relevant information. This includes financial results, company updates and other IR content – based exclusively on publicly available Fresenius disclosures.In an increasingly fast-paced and data-driven environment, digital investor relations play a key role in delivering timely, transparent and stakeholder-focused communication. AskFRE supports this ambition by enabling more intuitive access to financial information and tailored user interactions, while reinforcing the consistency and accessibility of Fresenius’ disclosures.With AskFRE, Fresenius underscores its commitment to advancing a best in class digital investor relations experience.AskFRE is now available: https://www.fresenius.com/AskFRE-Your-IR-Assistant
May 26, 2026 · Fresenius
-
2026 Annual General Meeting: Fresenius delivers strong performance in 2025 and proposes 5% increase in dividends
![]()
2026 Annual General Meeting: Fresenius delivers strong performance in 2025 and proposes 5% increase in dividends
Michael Sen, CEO of Fresenius, emphasized: “In the past financial year, we showed that Fresenius can deliver a strong performance even in an environment where volatility has become the norm.”
May 22, 2026 · Fresenius
-
#FutureFresenius: REJUVENATE in action – Excellent start to the year - demonstrating continued strength and resilient performance; Guidance reconfirmed
![]()
#FutureFresenius: REJUVENATE in action – Excellent start to the year - demonstrating continued strength and resilient performance; Guidance reconfirmed
Michael Sen, CEO of Fresenius: "Fresenius made an excellent start to 2026, delivering performance fully in line with our expectations and leading us to reconfirm our full‑year guidance.
May 06, 2026 · Fresenius
